OncoMatch/Clinical Trials/NCT05284539
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Is NCT05284539 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab for non small cell lung cancer.
Treatment: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab — The investigators want to evaluate the Efficay and Safety of Platinum-based Chemotherapy with or without immune checkpoint inhibitors for EGFR/ALK/ROS1 Positive NSCLC who Failed from First-Line Standard Treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR sensitizing mutation
EGFR/ALK/ROS1-sensitive mutations confirmed by an accredited local laboratory
Required: ALK sensitizing mutation
EGFR/ALK/ROS1-sensitive mutations confirmed by an accredited local laboratory
Required: ROS1 sensitizing mutation
EGFR/ALK/ROS1-sensitive mutations confirmed by an accredited local laboratory
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systematic therapy — first line
progressed from first line systematic therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with cluster of differentiation 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies.
Lab requirements
Blood counts
adequate bone marrow hematopoiesis
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate bone marrow hematopoiesis and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify